pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$BEAMBeam Therapeutics Inc.

$BEAM21.10+0.43%
Cambridge, MA, USupdated 3h ago

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Preclinical: 1Phase 2: 4
1Preclinical4Phase 2
Phase 2
BEAM-201
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Phase 2
BEAM-301
Glycogen Storage Disease 1A
Phase 2
BEAM-302
Alpha-1 Antitrypsin Deficiency (A1AD)
Phase 2
ristoglogene autogetemcel
Beta Thalassaemia
Preclinical
BEAM-304
Phenylketonuria (PKU)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 3, 2026
earnings
$BEAM21.10+0.43%
16d ago
Beam Therapeutics Inc. earnings
Beam Therapeutics Inc.
→
view all catalysts →

Active trials

  • phase2A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)recruitingn=106
  • —A Long-term Follow-up Study in Patients Who Received BEAM-101recruitingn=50
  • phase1This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjectsrecruitingn=30
  • phase2BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Diseaseactive not recruitingn=15
  • phase2A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)recruitingn=36
  • phase2A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)active not recruitingn=5
🐶 Hiring Signal
32 open roles at Beam Therapeutics Inc. →

Where Beam Therapeutics Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaHematology 3Metabolic 1
departmentCommercial 7Manufacturing / CMC 6Quality 4Legal & Compliance 3IT & Engineering 2Finance 1

News

  • Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
    Pfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.
    fiercebiotech · 1d ago
  • Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
    When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
    biospace · 6d ago
  • Beam’s base editing therapy for sickle cell hits goal in pivotal trial
    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
    biopharma_dive · 9d ago
  • Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
    Beam Therapeutics announced Tuesday that its base-edited sickle cell therapy succeeded in a clinical trial, meaning a third one-time therapy for the disease may soon enter the market. In Beam’s Pha…
    endpoints · 9d ago
  • Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
    Beam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA appl…
    biospace · 9d ago
  • STAT+: GLP-1s are given an FDA warning for rare eye condition risk
    The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”
    stat · 9d ago
  • Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
    Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…
    fiercebiotech · 9d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 9d ago
  • Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
    The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerat…
    biospace · 15d ago
  • Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misled
    Pioneering IVF technique to reduce the risk of children inheriting mitochondrial diseases is being marketed as a fertility procedure for older women, despite little evidence it works.
    stat · 17d ago
view all news mentions →
identifiers
ticker
$BEAM
SEC CIK
0001745999
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 48m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?